Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. is a biopharmaceutical company focused on precision cardiology through targeted RNA therapeutics for heart disease. The company develops therapies designed to deliver ribonucleic acid medicines directly to cardiac tissue, using a proprietary delivery platform that combines tissue-selective targeting with oligonucleotide precision. Its current pipeline centers on rare genetic cardiomyopathies, including ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy. Atrium Therapeutics also advances research programs aimed at additional rare cardiac conditions, reflecting its focus on genetically defined diseases with significant unmet medical need. Based in San Diego, California, Atrium Therapeutics operates as a specialist developer in the broader biotechnology sector, with a business model centered on translating RNA science into potential treatments for inherited heart disorders.
$7.67
-$0.15 (-1.92%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-412.58% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 70.9%, still solid. Margins contracted 291.3pp, which offsets some of the top-line progress.
Negative free cash flow of -$43M. The business is consuming cash, not generating it. Operating margin contracted 291.3pp YoY, cost discipline may be slipping.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$36M
▲ +70.9% YoY
Net Income (TTM)
-$93M
▼ -205.2% YoY
Op. Margin
-268.98%
▼ -291.3pp YoY
ROIC
-55.73%
▲ +69.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$57M
▼ -86.6% YoY
Op. Cash Flow (TTM)
-$53M
▼ -86.0% YoY
Net Debt
-$266M
Net Cash Position
Cash & Equiv.
$270M
3Y CAGR: +26.4%
Continue Research
Is Atrium Therapeutics (RNA) overvalued?
Atrium Therapeutics (RNA)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Atrium Therapeutics scores 50/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Atrium Therapeutics a high-quality business?+
Atrium Therapeutics scores 50 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -269.0% operating margin and a -55.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Atrium Therapeutics a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh RNA's valuation and scores 50/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.